193 related articles for article (PubMed ID: 20021872)
21. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib-induced erythema multiforme: three cases.
Namba M; Tsunemi Y; Kawashima M
Eur J Dermatol; 2011; 21(6):1015-6. PubMed ID: 21926043
[No Abstract] [Full Text] [Related]
24. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
25. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
26. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
27. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
28. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
30. Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
Ruangkanchanasetr P; Kanjanapayak B; Jungmeechoke K
Nephrology (Carlton); 2011 Jan; 16(1):118-9. PubMed ID: 21175989
[No Abstract] [Full Text] [Related]
31. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
Jafri M; Douis H; Porfiri E
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
[No Abstract] [Full Text] [Related]
32. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Rey PM; Villavicencio H
Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
[TBL] [Abstract][Full Text] [Related]
33. Molecule of the month. Sorafenib.
Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
[No Abstract] [Full Text] [Related]
34. [Hepatocellular carcinoma management in the era of sorafenib].
Rosmorduc O
Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
[No Abstract] [Full Text] [Related]
35. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
[TBL] [Abstract][Full Text] [Related]
36. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
37. [Nexavar clinical registry].
Büchler T
Klin Onkol; 2010; 23(4):269-70. PubMed ID: 20806826
[No Abstract] [Full Text] [Related]
38. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
[TBL] [Abstract][Full Text] [Related]
39. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
[No Abstract] [Full Text] [Related]
40. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
